Jacob Johnson
Stock Analyst at Stephens & Co.
(3.49)
# 689
Out of 4,818 analysts
77
Total ratings
42.37%
Success rate
5.97%
Average return
Main Sectors:
Stocks Rated by Jacob Johnson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| STE STERIS | Reiterates: Overweight | $240 | $223.87 | +7.21% | 7 | Feb 6, 2025 | |
| MASS 908 Devices | Reiterates: Overweight | $6 | $5.40 | +11.11% | 4 | Jan 15, 2025 | |
| LFCR Lifecore Biomedical | Reiterates: Equal-Weight | $6 | $6.34 | -5.36% | 4 | Jan 3, 2025 | |
| AZTA Azenta | Reiterates: Overweight | $60 | $25.80 | +132.56% | 6 | Jan 2, 2025 | |
| DHR Danaher | Reiterates: Overweight | $315 | $196.31 | +60.46% | 2 | Oct 23, 2024 | |
| TMO Thermo Fisher Scientific | Initiates: Overweight | $680 | $431.64 | +57.54% | 1 | Oct 1, 2024 | |
| RGEN Repligen | Reiterates: Overweight | $170 | $141.40 | +20.23% | 4 | Jul 30, 2024 | |
| TKNO Alpha Teknova | Reiterates: Overweight | $5 | $6.43 | -22.24% | 5 | Jul 10, 2024 | |
| MXCT MaxCyte | Reiterates: Overweight | $11 | $2.82 | +290.76% | 5 | Apr 23, 2024 | |
| STVN Stevanato Group | Reiterates: Overweight | $38 | $21.81 | +74.23% | 2 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $17 | $5.59 | +204.11% | 3 | Mar 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $2.5 | $1.37 | +82.48% | 3 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $92 → $87 | $50.16 | +73.44% | 10 | Feb 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $420 → $390 | $218.18 | +78.75% | 8 | Oct 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $16 → $18 | $9.91 | +81.63% | 5 | Aug 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $6 | $2.28 | +163.16% | 2 | Jul 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $27 → $29 | $24.39 | +18.90% | 3 | Jul 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $153 → $130 | $105.76 | +22.92% | 2 | May 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $377 | $109.00 | +245.87% | 1 | Apr 7, 2022 |
STERIS
Feb 6, 2025
Reiterates: Overweight
Price Target: $240
Current: $223.87
Upside: +7.21%
908 Devices
Jan 15, 2025
Reiterates: Overweight
Price Target: $6
Current: $5.40
Upside: +11.11%
Lifecore Biomedical
Jan 3, 2025
Reiterates: Equal-Weight
Price Target: $6
Current: $6.34
Upside: -5.36%
Azenta
Jan 2, 2025
Reiterates: Overweight
Price Target: $60
Current: $25.80
Upside: +132.56%
Danaher
Oct 23, 2024
Reiterates: Overweight
Price Target: $315
Current: $196.31
Upside: +60.46%
Thermo Fisher Scientific
Oct 1, 2024
Initiates: Overweight
Price Target: $680
Current: $431.64
Upside: +57.54%
Repligen
Jul 30, 2024
Reiterates: Overweight
Price Target: $170
Current: $141.40
Upside: +20.23%
Alpha Teknova
Jul 10, 2024
Reiterates: Overweight
Price Target: $5
Current: $6.43
Upside: -22.24%
MaxCyte
Apr 23, 2024
Reiterates: Overweight
Price Target: $11
Current: $2.82
Upside: +290.76%
Stevanato Group
Mar 25, 2024
Reiterates: Overweight
Price Target: $38
Current: $21.81
Upside: +74.23%
Mar 13, 2024
Reiterates: Equal-Weight
Price Target: $17
Current: $5.59
Upside: +204.11%
Mar 7, 2024
Reiterates: Equal-Weight
Price Target: $2.5
Current: $1.37
Upside: +82.48%
Feb 2, 2024
Maintains: Overweight
Price Target: $92 → $87
Current: $50.16
Upside: +73.44%
Oct 27, 2023
Maintains: Overweight
Price Target: $420 → $390
Current: $218.18
Upside: +78.75%
Aug 21, 2023
Upgrades: Overweight
Price Target: $16 → $18
Current: $9.91
Upside: +81.63%
Jul 21, 2023
Reiterates: Overweight
Price Target: $6
Current: $2.28
Upside: +163.16%
Jul 17, 2023
Maintains: Overweight
Price Target: $27 → $29
Current: $24.39
Upside: +18.90%
May 16, 2022
Maintains: Overweight
Price Target: $153 → $130
Current: $105.76
Upside: +22.92%
Apr 7, 2022
Initiates: Overweight
Price Target: $377
Current: $109.00
Upside: +245.87%